NCT00599924View on ClinicalTrials.gov

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Colorectal NeoplasmsNeoplasms
Interventions
DRUG

sunitinib + FOLFOX

37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)

DRUG

sunitinib + FOLFOX

50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)

DRUG

sunitinib + FOLFOX

50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)

DRUG

sunitinib + FOLFOX

37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)

DRUG

sunitinib + FOLFOX

50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)

DRUG

sunitinib + FOLFOX

37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)

DRUG

sunitinib + FOLFOX

25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)

Trial Locations (3)

37232

Pfizer Investigational Site, Nashville

75246

Pfizer Investigational Site, Dallas

80045

Pfizer Investigational Site, Aurora

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00599924 - Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors | Biotech Hunter | Biotech Hunter